Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q3 2023 · 10-Q
Revenue$10.09M$10.09M−11.6% vs Q3 2022 Net Income-$1.05M-$1.05MN/M vs Q3 2022 EPS Diluted-$0.07-$0.07N/M vs Q3 2022 Operating Income-$1,866,603N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$1,183,406−53.5% Margins · derivedOperating margin-18.5%−16.0 pt vs Q3 2022
Net margin-10.4%−6.8 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 13, 2023 · 44 d after period end